CWM
SRPT icon

Copia Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Copia Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$395 Hold
22
– – ﹤0.01% 539
2026
Q1 		$479 Sell
22
-7
-24% -$135 ﹤0.01% 499
2025
Q4 		$624 Hold
29
– – ﹤0.01% 489
2025
Q3 		$559 Hold
29
– – ﹤0.01% 452
2025
Q2 		$496 Sell
29
-11
-28% -$469 ﹤0.01% 441
2025
Q1 		$2.55K Buy
40
+20
+100% +$2.1K ﹤0.01% 372
2024
Q4 		$2.43K Buy
+20
New +$2.45K ﹤0.01% 350

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Copia Wealth Management's SRPT Position: Q2 2026 in Review

Copia Wealth Management held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 22 shares worth $395. The position accounts for ﹤0.01% of the portfolio, ranked #539.

Copia Wealth Management first reported a position in SRPT in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.55K in Q1 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Copia Wealth Management held 22 shares of Sarepta Therapeutics worth $395 as of Q2 2026.
  • Copia Wealth Management left its Sarepta Therapeutics share count unchanged in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Copia Wealth Management's portfolio in Q2 2026, its #539 holding.
  • Copia Wealth Management first reported a position in Sarepta Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Copia Wealth Management's Sarepta Therapeutics position peaked at $2.55K in Q1 2025.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Copia Wealth Management's 13F filing for Q2 2026, filed 18 Aug 2026.